Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727991 | 0.81 | SCD (0.67) | SCDDCTPP1 | |
| SCHEMBL726265 | 0.81 | SCD (0.67) | SCDDCTPP1 | |
| SCHEMBL726477 | 0.80 | SCD (0.74) | SCDDCTPP1 | |
| SCHEMBL728019 | 0.80 | SCD (0.66) | SCDDCTPP1 | |
| SCHEMBL728032 | 0.79 | SCD (0.64) | SCDDCTPP1 | |
| SCHEMBL937531 | 0.79 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL5597018 | 0.78 | SCD (0.63) | SCDDCTPP1 | |
| SCHEMBL935839 | 0.78 | SCD (0.77) | SCDDCTPP1 | |
| SCHEMBL936702 | 0.77 | SCD (0.75) | SCDDCTPP1 | |
| SCHEMBL937339 | 0.77 | SCD (0.67) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651616-B1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| US-8148378-B2 | Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal | XENON PHARMACEUTICALS INC. (CA) | 2012-04-03 | — | — | US | claimed |
| JP-4831577-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20090197890-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| US-7514436-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2009-04-07 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500715-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | XENON PHARMACEUTICALS INC. (CA) | 2006-09-14 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651616-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011653-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1651616-B1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | disclosed |
| US-8148378-B2 | Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal | XENON PHARMACEUTICALS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148378-B2 | Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal | XENON PHARMACEUTICALS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | XENON PHARMACEUTICALS INC. (CA) | 2006-09-14 | — | — | US | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1651616-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011653-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197890-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | GPR119, SCD5, GYS2 | SCD 5/4885DCTPP1 2439/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | SCD 1/4885DCTPP1 3458/4885 |
| US-20060205713-A1 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators | GPR119, SCD, CPT1A | SCD 2/4885DCTPP1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.